Published in Conn Med on May 01, 1999
Identification of a granulocytotropic Ehrlichia species as the etiologic agent of human disease. J Clin Microbiol (1994) 9.97
A critical appraisal of "chronic Lyme disease". N Engl J Med (2007) 7.84
Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an Ixodes scapularis tick bite. N Engl J Med (2001) 6.76
Human granulocytic ehrlichiosis in the upper Midwest United States. A new species emerging? JAMA (1994) 6.55
Direct cultivation of the causative agent of human granulocytic ehrlichiosis. N Engl J Med (1996) 5.35
Ixodes dammini as a potential vector of human granulocytic ehrlichiosis. J Infect Dis (1995) 5.26
Clinical and laboratory characteristics of human granulocytic ehrlichiosis. JAMA (1996) 4.88
Identification of a novel rickettsial infection in a patient diagnosed with murine typhus. J Clin Microbiol (1994) 4.06
Emergence of the ehrlichioses as human health problems. Emerg Infect Dis (1996) 3.89
Human granulocytic ehrlichiosis: a case series from a medical center in New York State. Ann Intern Med (1996) 3.41
Four clones of Borrelia burgdorferi sensu stricto cause invasive infection in humans. Infect Immun (1999) 3.41
Human disease in Europe caused by a granulocytic Ehrlichia species. J Clin Microbiol (1997) 3.28
Practice parameter: treatment of nervous system Lyme disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2007) 3.12
Outbreak of vancomycin-, ampicillin-, and aminoglycoside-resistant Enterococcus faecium bacteremia in an adult oncology unit. Antimicrob Agents Chemother (1994) 3.02
Natural history of colonization with vancomycin-resistant Enterococcus faecium. Infect Control Hosp Epidemiol (1995) 2.97
Frequency of puncture injuries in surgeons and estimated risk of HIV infection. Arch Surg (1989) 2.79
Impact of color blindness on recognition of blood in body fluids. Arch Intern Med (2001) 2.78
Adverse drug events and medication errors: detection and classification methods. Qual Saf Health Care (2004) 2.77
Serodiagnosis in early Lyme disease. J Clin Microbiol (1993) 2.69
Diagnosis of early Lyme disease by polymerase chain reaction amplification and culture of skin biopsies from erythema migrans lesions. J Clin Microbiol (1992) 2.69
Simultaneous human granulocytic ehrlichiosis and Lyme borreliosis. N Engl J Med (1997) 2.69
Infection due to Leuconostoc species: six cases and review. Rev Infect Dis (1990) 2.58
Lyme borreliosis. Lancet (1998) 2.57
Cloning and expression of the 44-kilodalton major outer membrane protein gene of the human granulocytic ehrlichiosis agent and application of the recombinant protein to serodiagnosis. J Clin Microbiol (1998) 2.44
Evolution of the serologic response to Borrelia burgdorferi in treated patients with culture-confirmed erythema migrans. J Clin Microbiol (1996) 2.43
Opportunistic infection in previously healthy women. Initial manifestations of a community-acquired cellular immunodeficiency. Ann Intern Med (1982) 2.41
Hemocytic rickettsia-like organisms in ticks: serologic reactivity with antisera to Ehrlichiae and detection of DNA of agent of human granulocytic ehrlichiosis by PCR. J Clin Microbiol (1995) 2.38
Genetic diversity of Borrelia burgdorferi in lyme disease patients as determined by culture versus direct PCR with clinical specimens. J Clin Microbiol (1999) 2.35
Positive Lyme disease serology in patients with clinical and laboratory evidence of human granulocytic ehrlichiosis. Am J Clin Pathol (1997) 2.35
Coexistence of antibodies to tick-borne pathogens of babesiosis, ehrlichiosis, and Lyme borreliosis in human sera. J Clin Microbiol (1995) 2.32
Transmission and passage in horses of the agent of human granulocytic ehrlichiosis. J Infect Dis (1995) 2.31
Antigenic diversity of granulocytic Ehrlichia isolates from humans in Wisconsin and New York and a horse in California. J Infect Dis (1997) 2.31
Ultrastructural and antigenic characterization of a granulocytic ehrlichiosis agent directly isolated and stably cultivated from a patient in New York state. J Infect Dis (1997) 2.26
Human granulocytic ehrlichiosis in Europe. Lancet (1995) 2.25
Geographic, clinical, serologic, and molecular evidence of granulocytic ehrlichiosis, a likely zoonotic disease, in Minnesota and Wisconsin dogs. J Clin Microbiol (1996) 2.14
Identification of the antigenic constituents of Ehrlichia chaffeensis. Am J Trop Med Hyg (1994) 2.13
PCR method for detection of adenovirus in urine of healthy and human immunodeficiency virus-infected individuals. J Clin Microbiol (1998) 2.12
ankA: an Ehrlichia phagocytophila group gene encoding a cytoplasmic protein antigen with ankyrin repeats. Infect Immun (2000) 2.02
Risk of nosocomial infection with human T-cell lymphotropic virus III (HTLV-III). N Engl J Med (1985) 1.99
Comparison of major antigenic proteins of six strains of the human granulocytic ehrlichiosis agent by Western immunoblot analysis. J Clin Microbiol (1997) 1.98
Human granulocytic ehrlichiosis in Connecticut: report of a fatal case. Clin Infect Dis (1995) 1.97
Human antibody responses to VlsE antigenic variation protein of Borrelia burgdorferi. J Clin Microbiol (1999) 1.95
Laboratory diagnostic techniques for patients with early Lyme disease associated with erythema migrans: a comparison of different techniques. Clin Infect Dis (2001) 1.94
Exposure to deer blood may be a cause of human granulocytic ehrlichiosis. Clin Infect Dis (1996) 1.94
Impact of genotypic variation of Borrelia burgdorferi sensu stricto on kinetics of dissemination and severity of disease in C3H/HeJ mice. Infect Immun (2001) 1.93
Ixodes pacificus (Acari: Ixodidae) as a vector of Ehrlichia equi (Rickettsiales: Ehrlichieae). J Med Entomol (1996) 1.89
Borrelia lonestari infection after a bite by an Amblyomma americanum tick. J Infect Dis (2001) 1.84
Serological evidence of human granulocytic ehrlichiosis in Norway. Eur J Clin Microbiol Infect Dis (1996) 1.84
Emerging bacterial zoonotic and vector-borne diseases. Ecological and epidemiological factors. JAMA (1996) 1.82
Leuconostoc, an emerging vancomycin-resistant pathogen. Lancet (1987) 1.80
Isolation of the equine granulocytic ehrlichiosis agent, Ehrlichia equi, in tick cell culture. J Clin Microbiol (1996) 1.79
Molecular cloning of the bombesin/gastrin-releasing peptide receptor from Swiss 3T3 cells. Proc Natl Acad Sci U S A (1991) 1.75
Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections. J Infect Dis (1995) 1.75
Antigenic characterization of ehrlichiae: protein immunoblotting of Ehrlichia canis, Ehrlichia sennetsu, and Ehrlichia risticii. J Clin Microbiol (1992) 1.74
Molecular typing of Borrelia burgdorferi from Lyme disease patients by PCR-restriction fragment length polymorphism analysis. J Clin Microbiol (1996) 1.73
Human granulocytic ehrlichiosis. Clin Infect Dis (2000) 1.72
Accuracy of IgM immunoblotting to confirm the clinical diagnosis of early Lyme disease. Arch Intern Med (1996) 1.71
Natural infection of small mammal species in Minnesota with the agent of human granulocytic ehrlichiosis. J Clin Microbiol (1997) 1.70
Protection against Ehrlichia equi is conferred by prior infection with the human granulocytotropic Ehrlichia (HGE agent). J Clin Microbiol (1995) 1.70
Identification of Ehrlichia in human tissue. N Engl J Med (1991) 1.69
Equine granulocytic ehrlichiosis in Connecticut caused by an agent resembling the human granulocytotropic ehrlichia. J Clin Microbiol (1996) 1.64
A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med (1996) 1.64
Inhibition of efficient polymerase chain reaction amplification of Borrelia burgdorferi DNA in blood-fed ticks. Am J Trop Med Hyg (1997) 1.63
Strongyloides stercoralis hyperinfection in a patient with the acquired immune deficiency syndrome. Am J Med (1987) 1.61
A limitation of 2-stage serological testing for Lyme disease: enzyme immunoassay and immunoblot assay are not independent tests. Clin Infect Dis (2000) 1.61
High frequency of false positive IgM immunoblots for Borrelia burgdorferi in clinical practice. Clin Microbiol Infect (2012) 1.60
Reinfection with the agent of human granulocytic ehrlichiosis. Ann Intern Med (1998) 1.60
Proposing a resolution to debates on diversity partitioning. Ecology (2012) 1.60
Acquired immunodeficiency syndrome in male prisoners. New insights into an emerging syndrome. Ann Intern Med (1983) 1.58
Human monocytic and granulocytic ehrlichioses. Discovery and diagnosis of emerging tick-borne infections and the critical role of the pathologist. Arch Pathol Lab Med (1997) 1.58
Risk of hepatitis E infection to travelers. J Travel Med (2000) 1.58
Serratia plymuthica sepsis associated with infection of central venous catheter. J Clin Microbiol (1987) 1.57
Comparative pathology, and immunohistology associated with clinical illness after Ehrlichia phagocytophila-group infections. Am J Trop Med Hyg (2000) 1.55
Differential effects on growth, cell cycle arrest, and induction of apoptosis by resveratrol in human prostate cancer cell lines. Exp Cell Res (1999) 1.54
Ehrlichia equi infection of horses from Minnesota and Wisconsin: detection of seroconversion and acute disease investigation. J Vet Intern Med (2000) 1.54
Seroprevalence of human granulocytic ehrlichiosis among permanent residents of northwestern Wisconsin. Clin Infect Dis (1998) 1.54
Prophylactic use of antibiotics for procedures after total joint replacement. J Bone Joint Surg Am (1996) 1.52
Granulocytic Ehrlichiae in Ixodes persulcatus ticks from an area in China where Lyme disease is endemic. J Clin Microbiol (2000) 1.49
'Normal' CSF in bacterial meningitis. JAMA (1980) 1.46
Temporal relation between Ixodes scapularis abundance and risk for Lyme disease associated with erythema migrans. Am J Epidemiol (1999) 1.46
Isolation of Borrelia burgdorferi from the blood of seven patients with Lyme disease. Am J Med (1990) 1.46
Gastrointestinal manifestations of the acquired immunodeficiency syndrome: a review of 22 cases. Am J Gastroenterol (1985) 1.45
Trimethoprim-sulfamethoxazole in the United States. Ann Intern Med (1979) 1.45